FDA clears Bioness' StimRouter device for chronic pain

The FDA has granted market clearance to Bioness' StimRouter device for the treatment of chronic peripheral pain.

The FDA has granted market clearance for Bioness' Stimrouter for the treatment of chronic peripheral pain.

The company describes StimRouter as a minimally invasive, implanted neuromodulation device that sends electrical signals to the pain's point of origin. The device is controlled by a wireless, hand-held unit.

Bioness Inc., Food & Drug Administration (FDA)

News Well, Neuromodulation/Neurostimulation, Regulatory

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1Bqi0sT